blinatumomab, ponatinib, Philadelphia Chromosome, bcr-abl1, ALL
myelodysplastic syndromes, MDS, oral decitabine, venetoclax, chronic myelomonocytic leukemia, CMML
Philadelphia-negative ALL, inotuzumab, blinatumomab, chemo-immunotherapy, salvage, outcome
Area deprivation index, racial/ethnic disparity, clinical trials, stem cell transplant